ATE530193T1 - Verfahren zur steigerung der klasse i präsentation von exogenen antigene durch humane dendritische zellen - Google Patents

Verfahren zur steigerung der klasse i präsentation von exogenen antigene durch humane dendritische zellen

Info

Publication number
ATE530193T1
ATE530193T1 AT01933328T AT01933328T ATE530193T1 AT E530193 T1 ATE530193 T1 AT E530193T1 AT 01933328 T AT01933328 T AT 01933328T AT 01933328 T AT01933328 T AT 01933328T AT E530193 T1 ATE530193 T1 AT E530193T1
Authority
AT
Austria
Prior art keywords
dendritic cells
presentation
processing
class
population
Prior art date
Application number
AT01933328T
Other languages
English (en)
Inventor
Michael Salgaller
Alton Boynton
Original Assignee
Northwest Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics Inc filed Critical Northwest Biotherapeutics Inc
Application granted granted Critical
Publication of ATE530193T1 publication Critical patent/ATE530193T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4276—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/4528—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01933328T 2000-05-12 2001-05-11 Verfahren zur steigerung der klasse i präsentation von exogenen antigene durch humane dendritische zellen ATE530193T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20375800P 2000-05-12 2000-05-12
PCT/US2001/015428 WO2001087325A1 (en) 2000-05-12 2001-05-11 Method to increase class i presentation of exogenous antigens by human dendritic cells

Publications (1)

Publication Number Publication Date
ATE530193T1 true ATE530193T1 (de) 2011-11-15

Family

ID=22755184

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01933328T ATE530193T1 (de) 2000-05-12 2001-05-11 Verfahren zur steigerung der klasse i präsentation von exogenen antigene durch humane dendritische zellen

Country Status (11)

Country Link
US (2) US20030175247A1 (de)
EP (2) EP1292321B1 (de)
JP (4) JP4841794B2 (de)
AT (1) ATE530193T1 (de)
AU (3) AU2001259760B2 (de)
CA (1) CA2407104A1 (de)
DK (2) DK1292321T3 (de)
ES (2) ES2375948T3 (de)
IL (4) IL152655A0 (de)
NZ (1) NZ522807A (de)
WO (1) WO2001087325A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE530193T1 (de) * 2000-05-12 2011-11-15 Northwest Biotherapeutics Inc Verfahren zur steigerung der klasse i präsentation von exogenen antigene durch humane dendritische zellen
PT1441591T (pt) * 2001-09-06 2016-10-06 Northwest Biotherapeutics Inc Composições e métodos para ativaçao linfocitária de células dendríticas monocíticas e células para resposta th-1
AU2013201707B2 (en) * 2001-09-06 2017-04-27 Northwest Biotherapeutics, Inc. Compositions and methods for priming monocytic dendritic cells and T cells for Th-1 response
ES2559002T3 (es) 2001-10-23 2016-02-10 Psma Development Company, L.L.C. Anticuerpos contra PSMA
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
ATE454447T1 (de) * 2001-11-30 2010-01-15 Us Gov Health & Human Serv Peptidagonisten für prostata-spezifisches antigen und ihre verwendung
EP1462456A4 (de) * 2001-12-10 2005-09-21 Greenpeptide Co Ltd Tumorantigene
JP4624377B2 (ja) * 2001-12-10 2011-02-02 株式会社グリーンペプタイド 腫瘍抗原
AU2003293411B2 (en) * 2002-12-06 2010-10-28 Northwest Biotherapeutics, Inc. Administration of dendritic cells partially matured in vitro for the treatment of tumors
CA2721169A1 (en) * 2008-04-14 2009-10-22 Proscan Rx Pharma Inc. Prostate specific membrane antigen antibodies and antigen binding fragments
US8728465B2 (en) * 2008-06-17 2014-05-20 Cedars-Sinai Medical Center Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
WO2010027513A2 (en) 2008-09-08 2010-03-11 Psma Development Company, Llc Methods for killing psma-expressing, taxane-resistant cancer cells
US8728806B2 (en) 2008-12-06 2014-05-20 The Board Of Regents, The University Of Texas System Methods and compositions related to Th-1 dendritic cells
US8858952B2 (en) 2009-02-19 2014-10-14 Mayo Foundation For Medical Education And Research Methods and materials for generating T cells
WO2011084479A1 (en) * 2009-12-15 2011-07-14 Immuneregen Biosciences, Inc. Substance p and analogs thereof as adjuvant therapy for adoptive cellular immunotherapy
RU2530523C2 (ru) * 2012-03-29 2014-10-10 Олег Борисович Егоров Способ противоопухолевой иммунотерапии
KR101985769B1 (ko) 2013-03-15 2019-06-04 동우 화인켐 주식회사 마스크리스 디지털 노광 방식을 통한 컬러 필터의 제조 방법
GB201315321D0 (en) * 2013-08-28 2013-10-09 Koninklijke Nederlandse Akademie Van Wetenschappen Transduction Buffer
EA035259B1 (ru) * 2014-02-14 2020-05-21 Иммьюн Дизайн Корп. Иммунотерапия рака с применением комбинации местной и системной иммунной стимуляции
DE102015106810A1 (de) 2015-04-30 2016-11-03 Infineon Technologies Ag Implantierbare Vorrichtung und implantierbares System mit dieser
GB201521101D0 (en) 2015-11-30 2016-01-13 Koninklijke Nederlandse Akademie Van Wetenschappen Transduction buffer
CN114246942A (zh) * 2020-09-24 2022-03-29 刘慧宁 肿瘤复合抗原、树突状细胞多价疫苗及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3753357A (en) 1970-12-14 1973-08-21 Ovitron Res Corp Method and apparatus for the preservation of cells and tissues
US4199022A (en) 1978-12-08 1980-04-22 The United States Of America As Represented By The Department Of Energy Method of freezing living cells and tissues with improved subsequent survival
US4559298A (en) 1982-11-23 1985-12-17 American National Red Cross Cryopreservation of biological materials in a non-frozen or vitreous state
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
CA2051092C (en) 1990-09-12 2002-07-23 Stephen A. Livesey Method and apparatus for cryopreparation, dry stabilization and rehydration of biological suspensions
US5227471A (en) 1992-01-30 1993-07-13 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Monoclonal antibody PD41 that binds to a prostate mucin antigen that is expressed in human prostatic carcinoma
EP0633929B1 (de) * 1992-04-01 2004-03-03 The Rockefeller University Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
AU4678993A (en) 1992-07-16 1994-02-14 Board Of Trustees Of The Leland Stanford Junior University Methods for using dendritic cells to activate t cells
JP3908271B2 (ja) * 1993-03-05 2007-04-25 エピミューン，インコーポレイティド Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US6130087A (en) 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
AU5898400A (en) * 1999-06-29 2001-01-31 Epimmune, Inc. Hla binding peptides and their uses
ATE530193T1 (de) * 2000-05-12 2011-11-15 Northwest Biotherapeutics Inc Verfahren zur steigerung der klasse i präsentation von exogenen antigene durch humane dendritische zellen

Also Published As

Publication number Publication date
AU2001259760B2 (en) 2006-10-05
JP2015108018A (ja) 2015-06-11
DK1292321T3 (da) 2012-01-30
JP2003533486A (ja) 2003-11-11
HK1161977A1 (en) 2012-08-17
JP2014001244A (ja) 2014-01-09
AU5976001A (en) 2001-11-26
EP1292321A1 (de) 2003-03-19
WO2001087325A1 (en) 2001-11-22
IL152655A (en) 2014-03-31
CA2407104A1 (en) 2001-11-22
IL248493A0 (en) 2016-11-30
NZ522807A (en) 2004-11-26
ES2375948T3 (es) 2012-03-07
AU2007200049A1 (en) 2007-01-25
DK2363139T3 (en) 2016-05-30
IL152655A0 (en) 2003-06-24
US20030175247A1 (en) 2003-09-18
US20080171023A1 (en) 2008-07-17
EP1292321A4 (de) 2005-09-21
JP2011225628A (ja) 2011-11-10
ES2571979T3 (es) 2016-05-27
EP2363139A1 (de) 2011-09-07
IL231081A (en) 2016-11-30
EP2363139B1 (de) 2016-03-02
JP4841794B2 (ja) 2011-12-21
IL231081A0 (en) 2014-03-31
EP1292321B1 (de) 2011-10-26

Similar Documents

Publication Publication Date Title
ATE530193T1 (de) Verfahren zur steigerung der klasse i präsentation von exogenen antigene durch humane dendritische zellen
Zhou et al. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells.
Hunter et al. Histochemical demonstration of enzymes separated by zone electrophoresis in starch gels
Gerner et al. Phenotypic and functional differentiation of porcine αβ T cells: current knowledge and available tools
Blank et al. Parasitism of epidermal Langerhans cells in experimental cutaneous leishmaniasis with Leishmania major
BRPI0212545A8 (pt) método ex vivo ou in vitro para produzir uma população de célula dendrítica madura e método para produzir células t
ATE411380T1 (de) Verfahren zur herstellung gebrauchsfertiger, antigenbeladener oder -unbeladener, kryokonservierter, reifer dendritischer zellen
Smit et al. The role of intestinal dendritic cells subsets in the establishment of food allergy
CA2368855A1 (en) Differentiation of monocytes into functional dendritic cells
DE69333433D1 (de) Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
JP2005532803A5 (de)
Bautista et al. Characterization and functional analysis of skin-derived dendritic cells from swine without a requirement for in vitro propagation
Rustemeyer et al. Human T lymphocyte priming in vitro by haptenated autologous dendritic cells
Brabants et al. An accelerated, clinical-grade protocol to generate high yields of type 1-polarizing messenger RNA–loaded dendritic cells for cancer vaccination
Sjaastad et al. Reduced T cell priming in microbially experienced “Dirty” mice results from limited IL-27 production by XCR1+ dendritic cells
CN113101303B (zh) 自发性凋亡的间充质干细胞的制备方法及用途
Coutant et al. Early changes in murine epidermal cell phenotype by contact sensitizers.
Menay et al. Extracellular vesicles derived from antigen-presenting cells pulsed with foot and mouth virus vaccine-antigens act as carriers of viral proteins and stimulate B cell response
US20150152385A1 (en) Tissue constructs and uses thereof
Guironnet et al. In vitro human T cell sensitization to haptens by monocyte-derived dendritic cells
CN109106945A (zh) 用于治疗疾病的同种异体自噬体富集组合物
JP2004520033A (ja) 分化拘束された成熟樹状細胞の調製用補助組成物
CN101760446B (zh) 制备单核细胞型干细胞的方法及应用
WO2003073827A3 (en) Methods of modulating dendritic cells using adjuvants
CN117024568A (zh) 一种atp响应型疫苗功能化框架核酸及其应用